Healthcare >> CEO Interviews >> October 5, 2000
THOMAS G. WIGGANS has served as President, Chief Executive Officer and a
Director of Connetics Corporation since July 1994, contributing over 25
years of experience in the biopharmaceutical industry. Prior to joining
Connetics, Mr. Wiggans was President and Chief Operating Officer of
CytoTherapeutics from 1992 to 1994. From 1980 to 1992, he held various
positions at Ares-Serono Group, including President of its US
pharmaceutical operations and Managing Director of its UK pharmaceutical
operations. Mr. Wiggans also served in various sales and marketing
positions with Eli Lilly & Co. Currently he is a Director of the
Biotechnology Industry Organization and a governing member of its
emerging company section. Mr. Wiggans is a Director of Paladin Labs,
Inc. and DJ Pharma, Inc. He holds a BS from the University of Kansas and
an MBA from Southern Methodist University. Profile
John L. Higgins is President, Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer and Executive Vice President, Finance, Administration and Corporate Development, of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Currently he is a Director on the boards of Techne Corporation, CoMentis and BioCryst, and serves as Chairperson on the BioCryst audit committee. Prior to BioCryst, Mr. Higgins was a member of the health care banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves as a Director of numerous public and private companies. He graduated magna cum laude from Colgate University with an B.A. in economics. Profile
including its history, products, development, markets, and your view of
the firm's future potential?
Mr. Wiggans: The company
